Emer Simic, partner in the firm’s Intellectual Property group, was recently quoted in the Bloomberg Law article "Biogen’s Rehearing Denial Lays New Hurdles for Pharma Patents."  Emer discusses the Federal Circuit's ruling in Biogen International GmbH v. Mylan Pharmaceuticals Inc., which signals to patent challengers that written description is now potentially a more attractive basis to challenge pharmaceutical patents.